Cancer drug vismodegib tested for Long-Term use in small study
NCT ID NCT00959647
First seen May 08, 2026 · Last updated Jun 22, 2026 · Updated 8 times
Summary
This study looked at the long-term safety of the cancer drug vismodegib in 19 patients with ovarian cancer, basal cell carcinoma, or metastatic colorectal cancer. All participants had previously taken vismodegib in an earlier Genentech trial and were expected to benefit from continued treatment. The main goal was to track side effects and see how many patients stopped treatment due to them.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital
Oakland, California, 94609, United States
-
Comprehensive Cancer Care
Palm Springs, California, 92262, United States
-
DermSurgery Associates, PA
Houston, Texas, 77030, United States
-
Irfan Firdaus, D.O.
Cincinnati, Ohio, 45242, United States
-
Johns Hopkins Univ Med Center
Baltimore, Maryland, 21231, United States
-
Karmanos Cancer Institute..
Detroit, Michigan, 48201, United States
-
Nevada Cancer Research Foundation
Las Vegas, Nevada, 89169, United States
-
Stanford Univ Medical Center
Stanford, California, 94305, United States
-
TGen Clinical Research Srvs
Scottsdale, Arizona, 85258, United States
-
University Of Michigan
Ann Arbor, Michigan, 48109-0934, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vismodegib (also known as Erivedge)
What this could lead to
If successful, this study could show that long-term vismodegib treatment is safe and helps control certain cancers.
What could go wrong
This is a small, early-phase extension study with only 19 participants, so results may not apply broadly. Side effects are possible and the drug may not work for everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.